Regal Assets Analytics

ARMO Biosciences (ARMO) – SanaCurrents Case Study

By |2020-04-23T10:19:50-04:00August 25th, 2018|Tags: , |

ARMO Biosciences (ARMO) listed in January 2018 at $17 per share. The company had a phase III pancreatic cancer drug [...]

Eiger Biopharmaceuticals (NASDAQ:EIGR) – SanaCurrents Case Study

By |2020-04-23T10:19:27-04:00August 10th, 2018|Tags: , |

Eiger Biopharmaceuticals (NASDAQ:EIGR), a company developing treatment for rare diseases, which often are reimbursed at a premium price, published a [...]

MyoKardia (NASDAQ:MYOK) – SanaCurrents Case Study

By |2018-11-25T13:52:30-05:00August 3rd, 2018|Tags: , , |

MyoKardia (NASDAQ:MYOK), a leading precision cardiovascular medicine company, reported good data during 2015-16 on its drug, mavacamten, to treat hypertrophic [...]

Dynavax’s (NASDAQ:DVAX) – SanaCurrents Case Study

By |2018-11-20T15:37:46-05:00August 1st, 2018|Tags: , , |

Dynavax's (NASDAQ:DVAX) BLA application for its Hepatitis B vaccine first received a complete response letter from the FDA in 2013 [...]

Zogenix (NASDAQ:ZGNX) – SanaCurrents Case Study

By |2018-11-20T15:51:47-05:00July 31st, 2018|Tags: , , , |

California-based company Zogenix (NASDAQ:ZGNX) observed the drug fenfluramine, which had problematic side effects in obesity, and demonstrated it could work [...]

Go to Top